script.reportAU
Other

Human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

PBAC's latest decision on Human papillomavirus (types 6, 11, 16, 18) recombinant vaccine: Recommended with restriction (2011). Considered for prevention of human papillomavirus (HPV) in males aged 12 to 13 years and a catch-up program over 2 years for Year 9 males.

PBAC outcome
Recommended with restriction
2011
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 2 submissions
Submissions
2
first 2006
Submissions
2
2006 → 2011

Eligible population

males aged 12 to 13 years and a catch-up program for Year 9 males

Therapy area
Other
Evidence base
RCT
Key trials
Protocol 016, Protocol 018, Protocol 020
Comparator
placebo (no vaccination) in males; secondary comparator: female-only vaccination
Economic model
CUA
ICER note
PBAC rejected the submitted base case as overly optimistic. The PBAC considered that a more likely incremental ratio might be in the range of $15,000–$45,000 per extra QALY gained, excluding penile cancer and HPV-related oropharyngeal cancer.
ICER basis
Range aggregates 2 submissions (2006–2011) — not a single base case.

Submission history

Open on full dashboard →